ADPT

SEC source: 0001209191-20-065257 · doc4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

SEC source: 0001209191-20-065103 · doc4.xml · derivative · entry 13

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 455,000

Underlying: Common Stock · 15,000 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F9 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-065103 · doc4.xml · nonDerivative · entry 10

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $65.30 to 65.50, inclusive.

SEC source: 0001209191-20-065103 · doc4.xml · nonDerivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,029

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.29 to 65.25, inclusive.

SEC source: 0001209191-20-065103 · doc4.xml · nonDerivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,535

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.28 to 64.25, inclusive.

SEC source: 0001209191-20-065103 · doc4.xml · nonDerivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

SEC source: 0001209191-20-065103 · doc4.xml · derivative · entry 12

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 470,000

Underlying: Common Stock · 15,000 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F9 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-065103 · doc4.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.98 to 64.58, inclusive.

SEC source: 0001209191-20-065103 · doc4.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,900

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.97 to 63.94, inclusive.

SEC source: 0001209191-20-065103 · doc4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

SEC source: 0001209191-20-065104 · doc4.xml · derivative · entry 7

HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 57,000 shares

Expires 2023-11-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-065104 · doc4.xml · nonDerivative · entry 3

HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.79 to 64.58, inclusive.

SEC source: 0001209191-20-065104 · doc4.xml · nonDerivative · entry 2

HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,486

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.79 to 63.785, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-065104 · doc4.xml · nonDerivative · entry 1

HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

SEC source: 0001209191-20-065103 · doc4.xml · derivative · entry 11

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 485,000

Underlying: Common Stock · 15,000 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F9 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-065103 · doc4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.42 to 59.95, inclusive.

SEC source: 0001209191-20-065103 · doc4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,323

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.42 to 59.40, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-065103 · doc4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

SEC source: 0001209191-20-065102 · doc4.xml · derivative · entry 3

Pellini Michael J · CIK 0001402017 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 25,000 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 7, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-065102 · doc4.xml · nonDerivative · entry 2

Pellini Michael J · CIK 0001402017 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020.

SEC source: 0001209191-20-065102 · doc4.xml · nonDerivative · entry 1

Pellini Michael J · CIK 0001402017 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020.

SEC source: 0001209191-20-065101 · doc4.xml · derivative · entry 3

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,667

Underlying: Common Stock · 417 shares

Expires 2027-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-065101 · doc4.xml · nonDerivative · entry 2

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-20-065101 · doc4.xml · nonDerivative · entry 1

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 417

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-20-063931 · doc4.xml · derivative · entry 5

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,000

Underlying: Common Stock · 2,000 shares

Expires 2029-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on May 6, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-063931 · doc4.xml · nonDerivative · entry 3

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.00 to 57.05, inclusive.

SEC source: 0001209191-20-063931 · doc4.xml · nonDerivative · entry 2

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.545 to 56.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-063931 · doc4.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020.

SEC source: 0001209191-20-063932 · doc4.xml · derivative · entry 4

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,000

Underlying: Common Stock · 2,000 shares

Expires 2023-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-063932 · doc4.xml · nonDerivative · entry 3

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.00 to 57.05, inclusive.

SEC source: 0001209191-20-063932 · doc4.xml · nonDerivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.545 to $56.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-063932 · doc4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.

SEC source: 0001387131-20-011164 · adpt-form4_121420.xml · nonDerivative · entry 1

VIKING GLOBAL INVESTORS LP · CIK 0001103804 · 10% owner

VIKING GLOBAL PERFORMANCE LLC · CIK 0001132625 · 10% owner

Viking Global Equities II LP · CIK 0001413378 · 10% owner

Viking Global Equities Master Ltd. · CIK 0001759530 · 10% owner

Viking Long Fund GP LLC · CIK 0001621607 · 10% owner

Viking Long Fund Master Ltd. · CIK 0001621596 · 10% owner

HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner

Ott David C. · CIK 0001621842 · 10% owner

Shabet Rose Sharon · CIK 0001711393 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 29,993,708

F1 · shares: On December 14, 2020, the Viking Funds (defined below) sold an aggregate of 1,000,000 shares of common stock of the Issuer ("Common Stock") at a price of $55.65 per share.VGE II sold 14,671 shares, VGEM sold 718,897 shares and VLFM sold 266,432 shares.

F2 · ownership.nature: O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP") and Viking Long Fund GP LLC ("VLFGP"). VGI provides managerial services to various investment funds, including Viking Global Equities II LP ("VGE II") and Viking Global Equities Master Ltd. ("VGEM") and Viking Long Fund Master Ltd. ("VLFM" and together with VLFM, VGEM and VGE II, the "Viking Funds").

F3 · ownership.nature: VGP is the general partner of VGE II. VLFGP serves as the investment manager of VLFM. Each of the Viking Funds, VGI, VGP, VLFGP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively, the "Reporting Persons") may be deemed to beneficially own the shares reported on this form.

F4 · ownership.nature: VGI provides managerial services to (i) VGE II, which directly holds 454,717 shares of Common Stock; (ii) VGEM, which directly holds 22,281,040 shares of Common Stock; and (iii) VLFM, which directly holds 8,257,951 shares of Common Stock. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares of Common Stock directly held by the Viking Funds.

F5 · ownership.nature: VGP is the general partner of VGE II and the investment manager of VGEM. Because of the relationships between VGP and VGE II and VGEM, respectively, VGP may be deemed to beneficially own the shares of Common Stock directly held by VGE II and VGEM.

F6 · ownership.nature: VLFGP serves as the investment manager of VLFM. Because of the relationship between VLFGP and VLFM, VLFGP may be deemed to beneficially own the shares of Common Stock directly held by VLFM.

F7 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001209191-20-063933 · doc4.xml · derivative · entry 6

HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,000

Underlying: Common Stock · 40,000 shares

Expires 2023-11-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-063933 · doc4.xml · nonDerivative · entry 2

HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020.

SEC source: 0001209191-20-063933 · doc4.xml · nonDerivative · entry 1

HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020.

SEC source: 0001209191-20-063930 · doc4.xml · derivative · entry 5

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,000

Underlying: Common Stock · 6,000 shares

Expires 2029-04-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-063930 · doc4.xml · nonDerivative · entry 4

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.25 to 59.90, inclusive.

SEC source: 0001209191-20-063930 · doc4.xml · nonDerivative · entry 3

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,651

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.25 to 59.24, inclusive.

SEC source: 0001209191-20-063930 · doc4.xml · nonDerivative · entry 2

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,018

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.08 to 57.99, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-063930 · doc4.xml · nonDerivative · entry 1

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020.

SEC source: 0001209191-20-063102 · doc4.xml · derivative · entry 3

SANG CHARLES · CIK 0001780656 · SVP, External Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,000

Underlying: Common Stock · 50,000 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-063102 · doc4.xml · nonDerivative · entry 2

SANG CHARLES · CIK 0001780656 · SVP, External Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.98 to 56.60, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-063102 · doc4.xml · nonDerivative · entry 1

SANG CHARLES · CIK 0001780656 · SVP, External Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-063101 · doc4.xml · derivative · entry 3

BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 25,000 shares

Expires 2024-10-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019.

F2 · derivative.exercise_date: All options are fully exercisable.

SEC source: 0001209191-20-063101 · doc4.xml · nonDerivative · entry 2

BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019.

SEC source: 0001209191-20-063101 · doc4.xml · nonDerivative · entry 1

BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019.

SEC source: 0001209191-20-062612 · doc4.xml · derivative · entry 5

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 490,000

Underlying: Common Stock · 30,000 shares

Expires 2025-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-062612 · doc4.xml · nonDerivative · entry 4

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019.

SEC source: 0001209191-20-062612 · doc4.xml · nonDerivative · entry 3

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,300

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $51.37 to 52.33, inclusive.